Apotex Moves First On Combigan As US Patent Expiry Looms
10 Orange Book Listed Patents Will Expire On 19 April
Executive Summary
Apotex has moved first on Allergan’s Combigan, introducing a US authorized generic as the clock ticks on the originator’s IP. Sandoz is among ANDA sponsors seemingly waiting for patent protection to lapse.
You may also be interested in...
What’s Next? Five Things To Look Out For In April
In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.
Sandoz sees a win on US Combigan appeal
Sandoz has gained a further advantage in its bid to introduce a generic of Allergan’s Combigan (brimonidine/timolol) 0.2%/0.5% eye drops in the US, following a favourable US Court of Appeals ruling.
Goldman Ends Endo Coverage Following Q2 EBITDA Guide
One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand.